Jasper Therapeutics, Inc. (JSPR): Cost of Revenue

Annual figures by period end, from SEC filings.

$41.63M

Year ended 2025-12-31

$23.31M

Trailing 12 months to 2026-06-30

2024-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$41.63M	+21.5%	2026-03-30, From 2025-01-01
2024-12-31	$34.27M	n/a	2026-03-30, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Jasper Therapeutics, Inc. (JSPR)	2025-12-31	$41.63M	+21.5%
Champions Oncology, Inc. (CSBR)	2026-04-30	$30.90M	+8.8%
Pluri Inc. (PLUR)	2026-06-30	$563.0K	-17.4%
Outlook Therapeutics, Inc. (OTLK)	2025-09-30	$1.36M	n/a
Alpha Cognition Inc. (ACOG)	2025-12-31	$603.4K	n/a
Entera Bio Ltd. (ENTX)	2025-12-31	$42.0K	-75.6%
Protalix BioTherapeutics, Inc. (PLX)	2025-12-31	$26.99M	+11.0%
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	$3.96M	+220.1%
Lineage Cell Therapeutics, Inc. (LCTX)	2024-12-31	$334.0K	-50.2%

Compare JSPR, CSBR, PLUR, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗